

12/1/2022

Medicare Part D Formulary Change

The product changes noted below will be implemented on the Medicare Part D Plan:

New Added Products: **Effective 12/1/2022**

Drug	Reason	Cost sharing**	Restrictions***
CALQUENCE (ACALABRUTINIB MALEATE) 100 MG TABLET	New Drug	Tier 5	PA QL LA
CAPLYTA 10.5 MG CAPSULE	New Drug	Tier 5	QL
CAPLYTA 21 MG CAPSULE	New Drug	Tier 5	QL
dabigatran etexilate 150 mg capsule	New Drug	Tier 4	
dabigatran etexilate 75 mg capsule	New Drug	Tier 4	
icosapent ethyl 0.5 gram capsule	New Drug	Tier 2	
IMBRUVICA 140 MG TABLET	Formulary Addition	Tier 5	PA QL
IMBRUVICA 70 MG/ML ORAL SUSPENSION	New Drug	Tier 5	PA QL
INGREZZA 40 MG CAPSULE	Formulary Addition	Tier 5	PA QL LA
INGREZZA 60 MG CAPSULE	Formulary Addition	Tier 5	PA QL LA
INGREZZA 80 MG CAPSULE	Formulary Addition	Tier 5	PA QL LA
INGREZZA INITIATION PACK 40 MG (7)-80 MG (21) CAPSULES IN A DOSE PACK	Formulary Addition	Tier 5	PA QL LA
lenalidomide 2.5 mg capsule	New Drug	Tier 5	PA QL
lenalidomide 20 mg capsule	New Drug	Tier 5	PA QL
mesalamine er 500 mg capsule,extended release	New Drug	Tier 5	

Future Removed Products: **There are no future removed products this month.**

Cost Sharing Tier Changes: **There were no cost sharing tier changes this month.**

**Consult your Medical provider for changes or recommendations to your medical care and prescription therapy

**Please consult the plan benefit design for copay/coinsurance amounts

***Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist [LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy PRF-C6T"